Linda J. W. Bosch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linda J. W. Bosch has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Gerrit A. Meijer
Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
21 shared publications - Oscar Krijgsman
Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands
20 shared publications - Daniela S. Thommen
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
19 shared publications - Diane Damotte
Université Paris Cité, APHP
19 shared publications - Egbert Frederik Smit
Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands
19 shared publications - François Goldwasser
Department of Medical Oncology, Cochin Hospital, Institut du Cancer Paris CARPEM, Université Paris Cité, AP-HP, Paris, France
19 shared publications
Latest Publications
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression signature, summary of training and validation results.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression signature, summary of training and validation results.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Coefficients of the PD-1T signature genes used in the prediction model.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Coefficients of the PD-1T signature genes used in the prediction model.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Data from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Purpose:Because PD-1 blockade is only effective in a minority of patients with advanced-stage non–small cell lung cancer (NSCLC), biomarkers are needed to guide treatment decisions. Tumor infiltration by PD-1T tumor-infiltrating lymphocytes (TIL), a dysfunctional TIL pool with tumor-reactive capacity, can be detected by digital quantitative IHC and has been established as a novel predictive biomarker in NSCLC. To facilitate translation of this biomarker to the clinic, we aimed to develop a robust RNA signature reflecting a tumor's PD-1T TIL status.Experimental Design:mRNA expression analysis using the NanoString nCounter platform was performed in baseline tumor samples from 41 patients with advanced-stage NSCLC treated with nivolumab that were selected on the basis of PD-1T TIL infiltration by IHC. Samples were included as a training cohort (n = 41) to develop a predictive gene signature. This signature was independently validated in a second cohort (n = 42). Primary outcome was disease control at 12 months (DC 12 m), and secondary outcome was progression-free and overall survival.Results:Regularized regression analysis yielded a signature using 12 out of 56 differentially expressed genes between PD-1T IHC-high tumors from patients with DC 12 m and PD-1T IHC-low tumors from patients with progressive disease (PD). In the validation cohort, 6/6 (100%) patients with DC 12 m and 23/36 (64%) with PD were correctly classified with a negative predictive value (NPV) of 100% and a positive predictive value of 32%.Conclusions:The PD-1T mRNA signature showed a similar high sensitivity and high NPV as the digital IHC quantification of PD-1T TIL. This finding provides a straightforward approach allowing for easy implementation in a routine diagnostic clinical setting.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Purpose:Because PD-1 blockade is only effective in a minority of patients with advanced-stage non–small cell lung cancer (NSCLC), biomarkers are needed to guide treatment decisions. Tumor infiltration by PD-1T tumor-infiltrating lymphocytes (TIL), a dysfunctional TIL pool with tumor-reactive capacity, can be detected by digital quantitative IHC and has been established as a novel predictive biomarker in NSCLC. To facilitate translation of this biomarker to the clinic, we aimed to develop a robust RNA signature reflecting a tumor's PD-1T TIL status.Experimental Design:mRNA expression analysis using the NanoString nCounter platform was performed in baseline tumor samples from 41 patients with advanced-stage NSCLC treated with nivolumab that were selected on the basis of PD-1T TIL infiltration by IHC. Samples were included as a training cohort (n = 41) to develop a predictive gene signature. This signature was independently validated in a second cohort (n = 42). Primary outcome was disease control at 12 months (DC 12 m), and secondary outcome was progression-free and overall survival.Results:Regularized regression analysis yielded a signature using 12 out of 56 differentially expressed genes between PD-1T IHC-high tumors from patients with DC 12 m and PD-1T IHC-low tumors from patients with progressive disease (PD). In the validation cohort, 6/6 (100%) patients with DC 12 m and 23/36 (64%) with PD were correctly classified with a negative predictive value (NPV) of 100% and a positive predictive value of 32%.Conclusions:The PD-1T mRNA signature showed a similar high sensitivity and high NPV as the digital IHC quantification of PD-1T TIL. This finding provides a straightforward approach allowing for easy implementation in a routine diagnostic clinical setting.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Patient characteristics and treatment outcomes for training and validation cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear association tests.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Patient characteristics and treatment outcomes for training and validation cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear association tests.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Overview of significantly expressed genes between tumors from PD-1T IHC high patients (n=12) and PD-1T IHC low patients (n=29).
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Overview of significantly expressed genes between tumors from PD-1T IHC high patients (n=12) and PD-1T IHC low patients (n=29).
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Correlation of the PD-1T signature with the Tumor Inflammation Signature (TIS). Correlation of the PD-1T signature and the TIS in the validation cohort (n=42).
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Correlation of the PD-1T signature with the Tumor Inflammation Signature (TIS). Correlation of the PD-1T signature and the TIS in the validation cohort (n=42).
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Patient characteristics and treatment outcomes for training and validation cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear association tests.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Patient characteristics and treatment outcomes for training and validation cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear association tests.